Healthcare / BiotechnologyNasdaqGM
$6.92
-0.62 (-8.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-51.4M · quality 48.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
27/100
D
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$203M
P/E
N/A
•EV/EBITDA
N/A
•ROE
103.2%
↑Gross Margin
N/A
•Debt/Equity
-0.10
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2014–2025 · 11 años de histórico normalizado
Revenue CAGR
-0.8%
FCF CAGR
—
FCF margin
-2838.6%
FCF / Net income
0.61x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $2.8M · net income $-130.3M · FCF $-79.4M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | $2.8M | $2.8M | $38.9M | $26.0M | $110.8M | $85.1M | $16.6M | $6.7M | $903000.00 | $207000.00 | $8.1M | $6.0M | $3.0M |
| Net Income | $-130.3M | $-130.3M | $-77.4M | $-219.7M | $35.4M | $-25.7M | $-68.9M | $-55.4M | $-65.3M | $-65.3M | $-36.2M | $-25.2M | $-12.9M |
| EBITDA | $-83.7M | $-83.7M | $-76.0M | $-235.0M | $39.1M | — | — | — | — | — | — | — | — |
| EPS | -5.02 | -5.02 | -4.49 | -49.76 | 3.00 | -6.60 | -20.40 | -36.60 | — | — | — | — | — |
| Operating Margin | -3099.9% | -3099.9% | -93.3% | -329.6% | 13.1% | -5.4% | -342.4% | -785.6% | -7200.7% | -30813.5% | -428.9% | -421.0% | -506.5% |
| Net Margin | -4658.6% | -4658.6% | -199.0% | -844.9% | 31.9% | -30.2% | -415.0% | -829.0% | -7235.4% | -31556.0% | -448.0% | -418.8% | -423.7% |
| Balance Sheet | |||||||||||||
| Debt/Equity | -0.10 | -0.10 | -2.06 | -0.02 | 0.40 | — | — | — | — | — | — | — | — |
| Current Ratio | 7.65 | 7.65 | — | — | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||||
| Free Cash Flow | $-79.4M | $-79.4M | $-32.8M | $-51.4M | $-32.8M | $-61.5M | $34.1M | $-51.5M | $-60.0M | $-52.8M | — | — | — |
| Returns | |||||||||||||
| ROE | 103.2% | 103.2% | 1138.3% | 49.9% | 37.7% | -114.1% | 382.5% | -659.2% | 1205.9% | -126.1% | -65.9% | 21.6% | 14.7% |
| Valuation | |||||||||||||
| P/E | — | — | — | — | 12.30 | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | — | — | 2.84 | — | — | — | — | — | — | — | — |
| P/B | — | — | — | — | 1.91 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||
| Revenue Growth | -92.8% | -92.8% | 49.6% | -76.5% | — | 412.6% | 148.6% | 639.4% | 336.2% | -97.4% | 34.5% | 97.7% | — |
| EPS Growth | -11.8% | -11.8% | 91.0% | -1758.7% | — | 67.6% | 44.3% | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-27.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-4.49 → -5.02
Residual
-27.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.